Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors

Research output: Contribution to journalReview article

4 Citations (Scopus)

Abstract

Tumors of nearly every origin activate the expression of genes normally restricted to gametogenic cells. These genes encode proteins termed cancer/testis (CT) antigens, since expression outside of their naturally immune-privileged site can evoke an immune response. Despite extensive efforts to exploit CT antigens as immunotherapeutic targets, investigation of whether these proteins participate in tumorigenic processes has lagged. Here, we discuss emerging evidence that demonstrates that CT antigens can confer a selective advantage to tumor cells by promoting oncogenic processes or permitting evasion of tumor-suppressive mechanisms. These advances indicate the inherent flexibility of tumor cell regulatory networks to engage aberrantly expressed proteins to promote neoplastic behaviors, which could ultimately present novel therapeutic entry points.

Original languageEnglish (US)
Pages (from-to)701-712
Number of pages12
JournalTrends in Cancer
Volume4
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Testicular Neoplasms
Antigens
Neoplasms
Proteins
Gene Expression
Therapeutics

Keywords

  • cancer germline genes
  • cancer/testis antigens
  • CT antigen function
  • CT antigens
  • CT genes
  • tumor antigens

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors. / Gibbs, Zane A.; Whitehurst, Angelique W.

In: Trends in Cancer, Vol. 4, No. 10, 01.10.2018, p. 701-712.

Research output: Contribution to journalReview article

@article{14462d6ed7ba412ab8627466b9dee5d4,
title = "Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors",
abstract = "Tumors of nearly every origin activate the expression of genes normally restricted to gametogenic cells. These genes encode proteins termed cancer/testis (CT) antigens, since expression outside of their naturally immune-privileged site can evoke an immune response. Despite extensive efforts to exploit CT antigens as immunotherapeutic targets, investigation of whether these proteins participate in tumorigenic processes has lagged. Here, we discuss emerging evidence that demonstrates that CT antigens can confer a selective advantage to tumor cells by promoting oncogenic processes or permitting evasion of tumor-suppressive mechanisms. These advances indicate the inherent flexibility of tumor cell regulatory networks to engage aberrantly expressed proteins to promote neoplastic behaviors, which could ultimately present novel therapeutic entry points.",
keywords = "cancer germline genes, cancer/testis antigens, CT antigen function, CT antigens, CT genes, tumor antigens",
author = "Gibbs, {Zane A.} and Whitehurst, {Angelique W.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.trecan.2018.08.005",
language = "English (US)",
volume = "4",
pages = "701--712",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "10",

}

TY - JOUR

T1 - Emerging Contributions of Cancer/Testis Antigens to Neoplastic Behaviors

AU - Gibbs, Zane A.

AU - Whitehurst, Angelique W.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Tumors of nearly every origin activate the expression of genes normally restricted to gametogenic cells. These genes encode proteins termed cancer/testis (CT) antigens, since expression outside of their naturally immune-privileged site can evoke an immune response. Despite extensive efforts to exploit CT antigens as immunotherapeutic targets, investigation of whether these proteins participate in tumorigenic processes has lagged. Here, we discuss emerging evidence that demonstrates that CT antigens can confer a selective advantage to tumor cells by promoting oncogenic processes or permitting evasion of tumor-suppressive mechanisms. These advances indicate the inherent flexibility of tumor cell regulatory networks to engage aberrantly expressed proteins to promote neoplastic behaviors, which could ultimately present novel therapeutic entry points.

AB - Tumors of nearly every origin activate the expression of genes normally restricted to gametogenic cells. These genes encode proteins termed cancer/testis (CT) antigens, since expression outside of their naturally immune-privileged site can evoke an immune response. Despite extensive efforts to exploit CT antigens as immunotherapeutic targets, investigation of whether these proteins participate in tumorigenic processes has lagged. Here, we discuss emerging evidence that demonstrates that CT antigens can confer a selective advantage to tumor cells by promoting oncogenic processes or permitting evasion of tumor-suppressive mechanisms. These advances indicate the inherent flexibility of tumor cell regulatory networks to engage aberrantly expressed proteins to promote neoplastic behaviors, which could ultimately present novel therapeutic entry points.

KW - cancer germline genes

KW - cancer/testis antigens

KW - CT antigen function

KW - CT antigens

KW - CT genes

KW - tumor antigens

UR - http://www.scopus.com/inward/record.url?scp=85053719310&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053719310&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2018.08.005

DO - 10.1016/j.trecan.2018.08.005

M3 - Review article

C2 - 30292353

AN - SCOPUS:85053719310

VL - 4

SP - 701

EP - 712

JO - Trends in Cancer

JF - Trends in Cancer

SN - 2405-8033

IS - 10

ER -